Other substances

Raltegravir

A HIV integrase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

5
 Supporting references
0
 Contradictory references
9
 AI-suggested references
0
 Clinical trials

General information

Raltegravir is used for treatment of human immunodeficiency virus (HIV) infection. It prevents viral genome integration into human DNA (NCIt).

Raltegravir on DrugBank
Raltegravir on PubChem
Raltegravir on Wikipedia

Marketed as

ISENTRESS (RALTEGRAVIR POTASSIUM); ISENTRESS HD (RALTEGRAVIR POTASSIUM)

 

Structure image - Raltegravir

CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F

Supporting references

Link Tested on Impact factor Notes Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model
Preprint In silico 		in silico Feb/02/2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
in silico Feb/22/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020
Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19
Spike protein Small molecule In silico 		in silico 3.26

Predicted to bind the SARS-CoV-2 spike protein RBD.

 Nov/06/2020
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
3CLpro RdRpol Small molecule In silico 		in silico 2.45

Predicted to bind both SARS-CoV-2 3C-like protease and RNA-dependent RNA polymerase. It also possesses predicted good bioavailability.

 Oct/26/2020

AI-suggested references

Link Publication date
Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2'-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs.
Mar/31/2022
Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies.
Aug/27/2021
Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase
Apr/20/2020
Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2
May/27/2020
Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2
May/20/2020
Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification
Feb/17/2022
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Mar/31/2021
Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study
Jun/23/2020
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
Jun/16/2020
Export (.csv)